EDMONTON, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a
growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and
cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its annual general
and special meeting of shareholders held on May 29, 2018 as per following results:
| Nominee |
|
Votes for |
|
Votes withheld |
|
% of votes cast |
| |
|
|
|
|
|
FOR |
|
WITHELD |
| Glenn Rourke |
|
14,547,962 |
|
366,358 |
|
97.54% |
|
2.46% |
| Gilles Gagnon |
|
14,318,305 |
|
596,015 |
|
96.00% |
|
4.00% |
| Donald Oborowsky |
|
14,434,462 |
|
479,858 |
|
96.78% |
|
3.22% |
| John Zupancic |
|
14,319,462 |
|
594,858 |
|
96.01% |
|
3.99% |
| Dr. Ulrich Kosciessa |
|
14,697,962 |
|
216,358 |
|
98.55% |
|
1.45% |
| Dr. William Li |
|
14,697,962 |
|
216,358 |
|
98.55% |
|
1.45% |
All other matters at the Shareholders' meeting, namely the appointment of auditors and the re-approval and
ratification of the Company’s Stock Option Plan as proposed in the Company’s information circular dated April 18, 2018, were also
approved by shareholders.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the
application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant
resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics
products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology,
biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and
drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E: jenene@jenenethomascommunications.com
Source: Ceapro Inc.
